Sensitive Europium Nanoparticle Based Time Resolved Fluorescence Immunoassay (ENIA) Assay Development for Detection of HIV-TB Co-infection

Friday, November 08, 2013 — Poster Session III
10:00 a.m. – 12:00 p.m.	FAES Academic Center (Upper-Level Terrace)	FDA/CBER	MICROBIO-5

Authors

MK Haleyur Giri Setty
SA Vemula
A Chunduri
EP Bulagonda
P Zhang
J Liu
B Du
JR Yarochana
AD Redd
M Vermeulen
TC Quinn
IK Hewlett

Abstract

Background: The syndemic interaction between the human immunodeficiency virus (HIV) and tuberculosis (TB) epidemics has had deadly consequences around the world. Early and accurate detection of HIV and TB co-infection is critical for epidemiological survey, incidence estimation and targeted intervention. Accurate assays that can identify incident infections and HIV-TB co-infections are a major unmet public health need. Methods: Peptides of HIV and TB antigenic proteins were coated on to microtiter plate wells to capture anti-HIV and anti-TB antibodies followed by binding to an anti-human antibody labeled with biotin molecules and streptavidin conjugated Eu3+ nanoparticles through biotin-SA interaction. Reactivity was measured by fluorescence from the resulting complex. Results: We have identified three HIV-1 Gp41 Pep scan peptides gp16, gp17 and gp18 from the region Gp76 -105 that react exclusively with samples from either acute or chronically infected individuals. Other peptides of p24, gp41 and Nef are also currently being analyzed similarly. We are testing TB- ESAT6 protein and other antigens on the ENIA platform. Conclusion: Our findings suggest ENIA platform can detect both HIV and TB with high sensitivity and specificity using as little as 1ul of plasma. The ENIA platform may be useful to evaluate HIV-TB co infection.